Today’s inhaled anesthetics hold a multibillion-dollar market despite causing many side effects such as dose-dependent cardiovascular depression, respiratory depression, post-operative nausea, and more. Can we find drugs with fewer of these challenges?
We say yes!
Expanesthetics is using a groundbreaking scientific discovery to develop new inhaled anesthetics with fewer side effects than today’s drugs.
Our team includes leaders in the fields of anesthetic science and clinical practice, as well as experienced and talented board directors, executives, advisors, and collaborators.
You can join over 125 other shareholders (including 80+ anesthesia clinicians)1 who have already invested in our vision and team. Register using the nearby form to read more2.
The US Securities and Exchange Commission rules under which we are operating require our investors to be "accredited." There are multiple criteria one can meet to fulfill this requirement. The most common are individuals making $200,000 or more (or couples making $300,000 or more) or individuals with a net worth of $1 million or more, excluding the value of their personal residence.
1 As of June 1, 2020.
2 This is not an offer to sell or a solicitation of any offer to buy any securities. Offers are made only by prospectus or other offering materials. Only prospective investors who have been invited to review such materials and meet the suitability standards required by law are eligible to invest. This document includes "forward-looking statements" within the meaning of the safe harbor provisions of the United States Private Securities Litigation Reform Act of 1995. These statements are based upon the current beliefs and expectations of Expanesthetics' management and are subject to significant risks and uncertainties. There can be no guarantees. These statements are made as of the date of this communication and Expanesthetics assumes no obligation to provide updates.